Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Apellis Pharmaceuticals Inc (NQ: APLS )

46.82 USD -0.32 (-0.68%)
Official Closing Price Updated: 5:11 PM EST, Dec 1, 2020 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 518,900
Open 48.25
Bid (Size) 45.00 (4)
Ask (Size) 50.00 (5)
Prev. Close 47.14
Today's Range 46.28 - 48.50
52wk Range 16.85 - 49.42
Shares Outstanding 55,941,896
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Apellis Pharmaceuticals to Present at the 2020 Evercore ISI HealthCONx Conference
From GlobeNewswire News Releases
Sobi and Apellis announce first patient dosed in potentially registrational ALS study of pegcetacoplan
- 52-week phase 2 MERIDIAN study to evaluate pegcetacoplan, a targeted C3 therapy, in approximately 200 adults with ALS 
From PR Newswire

Performance

YTD
+50.23%
+50.23%
1 Month
+48.40%
+48.40%
3 Month
+53.76%
+53.76%
6 Month
+39.01%
+39.01%
1 Year
+74.31%
+74.31%

More News

Read More
Apellis and Sobi Announce First Patient Dosed in Potentially Registrational ALS Study of Pegcetacoplan
From GlobeNewswire News Releases
Apellis Announces FDA Acceptance and Priority Review of the New Drug Application for Pegcetacoplan for the Treatment of PNH
From GlobeNewswire News Releases
Apellis Announces Late-Breaking Presentation of Largest Retrospective Database Study in Geographic Atrophy (GA) at AAO 2020 Virtual
From GlobeNewswire News Releases
Apellis Pharmaceuticals to Present at Upcoming Investor Conferences
From GlobeNewswire News Releases
Apellis to Present New Data Supporting the Efficacy and Safety of Pegcetacoplan in PNH at the American Society of Hematology Annual Meeting
From GlobeNewswire News Releases
Apellis Pharmaceuticals Reports Third Quarter 2020 Financial Results
From GlobeNewswire News Releases
Apellis and Sobi Enter Collaboration for Global Co-development and Ex-US Commercialization of Systemic Pegcetacoplan in Rare Diseases with Urgent Need for New Treatments
From GlobeNewswire News Releases
First Week of APLS July 2021 Options Trading
Tags Stocks
From Market News Video
Apellis Announces 18-Month Data from Phase 1b Study of Pegcetacoplan in Patients with Geographic Atrophy (GA)
From GlobeNewswire News Releases
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.